Some VCs Have Miles To Go While Others Have Burned What's In The Tank
This article was originally published in The Pink Sheet Daily
Executive Summary
A handful of life sciences venture capital funds, but not all of them, are thriving in an environment of cautious limited partner investing.
You may also be interested in...
Unnamed Lilly "Mirror Fund" Acquires First Two Compounds
The acquisitions of two drug candidates - one from Lilly, one from a university - are the first in the pharma's latest scheme to share risk with VCs.
Biotech Ventures Forth: Third Rock Rolls Out $426M Fund, Relypsa Reloads
It was a good day for biotech venture news, as early-stage investor Third Rock closed its second fund and Relypsa reported a massive $70 million Series B funding to push its potassium binding agent into pivotal trials.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.